# US 12,214,043 B2 · Therapeutic nanomaterials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,214,043 B2
- Document ID: US12214043B2
- Status: Granted
- Kind: B2
- Application number: 17/514,390
- Filed: 2021-10-29
- Published: 2022-05-05
- Granted: 2025-02-04
- Earliest claimed: 2020-10-29
- Applicants: University of Connecticut
- Inventors: Yupeng Chen; Jinhyung Lee; Wuxia Zhang
- Web page: https://patentgrep.com/patent/US12214043B2

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/721: Dextrans
- A61K 31/722: Chitin, chitosan
- A61K 31/727: Heparin; Heparan
- A61K 31/728: Hyaluronic acid
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/363: {Fibrinogen}
- A61K 38/385: {Serum albumin}
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.

## Claims

### Claim 1

A composition comprising a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or CH3;
R2 is (CH2)j, (CH2CH2O)k or (CH2CH2NH)m;
j, k, and m are the chemical subscripts for the moieties listed in R2 and each it independently represents 0-200 of the repeating moieties;
L is absent; and
X is folic acid
wherein the composition has a pH of about 1 to about 10.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the therapeutic agent is targeting molecule that is a surface targeting modifier, a membrane dipeptidase targeting molecule, an endoplasmic reticulum (ER) targeting molecule, a mitochondrial membrane targeting molecule, a nucleus targeting molecule.